title: Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
abstract: Combining antagonist/partial agonist activity at dopamine D2 and agonist activity at serotonin 5-HT1A receptors is one of the approaches that has recently been chosen to develop new generation antipsychotics, including bifeprunox, SSR181507 and SLV313. There have been, however, few comparative data on their pharmacological profiles. Here, we have directly compared a wide array of these novel dopamine D2/5-HT1A and conventional antipsychotics in rat models predictive of antipsychotic activity. Potency of antipsychotics to antagonize conditioned avoidance, methylphenidate-induced behaviour and D-amphetamine-induced hyperlocomotion correlated with their affinity at dopamine D2 receptors. Potency against ketamine-induced hyperlocomotion was independent of affinity at dopamine D2 or 5-HT1A receptors. Propensity to induce catalepsy, predictive of occurrence of extrapyramidal side effects, was inversely related to affinity at 5-HT1A receptors. As a result, preferential D2/5-HT1A antipsychotics displayed a large separation between doses producing 'antipsychotic-like' vs. cataleptogenic actions. These data support the contention that 5-HT1A receptor activation greatly reduces or prevents the cataleptogenic potential of novel antipsychotics. They also emphasize that interactions at 5-HT1A and D2 receptors, and the nature of effects (antagonism or partial agonism) at the latter has a profound influence on pharmacological activities, and is likely to affect therapeutic profiles.
authors.affiliation: Division of Neurobiology, Pierre Fabre Research Centre, Castres, France. laurent.bardin@pierre-fabre.com
authors.forename: Laurent
authors.initials: L
authors.lastname: Bardin
authors.forename: Agnès
authors.initials: A
authors.lastname: Auclair
authors.forename: Mark S
authors.initials: MS
authors.lastname: Kleven
authors.forename: Eric P M
authors.initials: EP
authors.lastname: Prinssen
authors.forename: Wouter
authors.initials: W
authors.lastname: Koek
authors.forename: Adrian
authors.initials: A
authors.lastname: Newman-Tancredi
authors.forename: Ronan
authors.initials: R
authors.lastname: Depoortère
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects*; D002375:Catalepsy / Q000139:chemically induced / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D003913:Dextroamphetamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004597:Electroshock; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007649:Ketamine / Q000494:pharmacology; D008297:Male; D008774:Methylphenidate / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D018691:Excitatory Amino Acid Antagonists; D017448:Receptors, Dopamine D2; D044282:Receptor, Serotonin, 5-HT1A; D008774:Methylphenidate; D007649:Ketamine; D003913:Dextroamphetamine